The Effects of Cilostazol on Peripheral Neuropathy in Diabetic Patients With Peripheral Arterial Disease

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Angiology

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0003319708321100PMID 18796444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

  2007cited by this paper
• Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

  2007cited by this paper
• Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

  2006cited by this paper
• The US experience with cilostazol in treating intermittent claudication.

  2005cited by this paper
• The global burden of diabetic foot disease.

  2005cited by this paper
• Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double‐blind, placebo‐controlled trial

  2004cited by this paper
• Reducing the incidence of foot ulceration and amputation in diabetes

  2004cited by this paper
• Cilostazol

  2003cited by this paper
• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.

  2003cited by this paper
• The pharmacology of cilostazol

  2002cited by this paper
• New Mechanism of Action for Cilostazol: Interplay Between Adenosine and Cilostazol in Inhibiting Platelet Activation

  2002cited by this paper
• Effect of Cilostazol in Patients with Intermittent Claudication: A Randomized, Double-Blind, Placebo-Controlled Study

  2002cited by this paper
• Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy.

  2002cited by this paper
• Analysis of the cilostazol safety database.

  2001cited by this paper
• Cilostazol: Treatment of Intermittent Claudication

  2001cited by this paper
• Interplay Between Inhibition of Adenosine Uptake and Phosphodiesterase Type 3 on Cardiac Function by Cilostazol, an Agent to Treat Intermittent Claudication

  2001cited by this paper
• The diabetic foot: a global view

  2000cited by this paper
• A comparison of cilostazol and pentoxifylline for treating intermittent claudication.

  2000cited by this paper
• A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.

  1999cited by this paper
• Effect of Cilostazol on the Neuropathies of Streptozotocin-Induced Diabetic Rats

  1999cited by this paper
• Improving prognosis in type 2 diabetes. Diabetic neuropathy is in trouble.

  1999cited by this paper
• Interaction Potential and Tolerability of the Coadministration of Cilostazol and Aspirin

  1999cited by this paper
• Effect of Cilostazol on the Pharmacokinetics and Pharmacodynamics of Warfarin

  1999cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats.

  1998cited by this paper
• Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.

  1998cited by this paper
• Costs and duration of care for lower extremity ulcers in patients with diabetes.

  1998cited by this paper
• Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.

  1998cited by this paper
• Lowering the risk of neuropathy, foot ulcers and amputations

  1998cited by this paper
• Cilostazol, a phosphodiesterase inhibitor for the treatment of diabetic neuropathy

  1997cited by this paper
• Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats.

  1997cited by this paper
• Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity

  1995cited by this paper
• Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes.

  1995cited by this paper
• Effect of cilostazol on experimental diabetic neuropathy in the rat

  1995cited by this paper
• Vascular factors in diabetic neuropathy

  1994cited by this paper
• Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism

  1994cited by this paper
• Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus

  1994cited by this paper
• Assessment and management of foot disease in patients with diabetes.

  1994cited by this paper
• The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort

  1993cited by this paper
• A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

  1993cited by this paper
• Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.

  1992cited by this paper
• Endoneurial capillary abnormalities in mild human diabetic neuropathy.

  1992cited by this paper
• Endoneurial Microvessels in Human Diabetic Neuropathy: Endothelial Cell Dysjunction and Lack of Treatment Effect by Aldose Reductase Inhibitor

  1991cited by this paper
• Morphometry of endoneurial capillaries in diabetic sensory and autonomic neuropathy

  1990cited by this paper
• Relationship of Endoneurial Capillary Abnormalities to Type and Severity of Diabetic Polyneuropathy

  1990cited by this paper
• The effect of acrylamide on the induction of ornithine decarboxylase in the dorsal root ganglion of the rat.

  1990cited by this paper
• Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy

  1989cited by this paper
• In vitro correction of impaired Na+-K+-ATPase in diabetic nerve by protein kinase C agonists.

  1989cited by this paper
• Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.

  1987cited by this paper
• Capillary number and percentage closed in human diabetic sural nerve.

  1985cited by this paper
• Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation.

  1979cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper

• HIỆU QUẢ CỦA CILOSTAZOL TRONG ĐIỀU TRỊ ĐAU CÁCH HỔI Ở BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2 CÓ BỆNH ĐỘNG MẠCH CHI DƯỚI

  2024cites this paper
• Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?

  2024cites this paper
• Benefits of Cilostazol’s Effect on Vascular and Neuropathic Complications Caused by Diabetes

  2024cites this paper
• Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats

  2024cites this paper
• Peripheral Nerve Denervation in Streptozotocin-Induced Diabetic Rats Is Reduced by Cilostazol

  2023cites this paper
• Cilostazol for intermittent claudication.

  2021cites this paper
• Effect of Neurodynamics on Pain and Paresthesia in Post-operated Patients with Lumbar Disc Herniation

  2020cites this paper
• Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions

  2019cites this paper
• Peripheral Artery Disease and Exercise in Patients with Diabetes

  2018cites this paper
• Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease

  2015influential citation
• Cilostazol for intermittent claudication.

  2014cites this paper
• Association of complement C3 and interleukin-1 with foot infections in diabetic patients.

  2012cites this paper
• Antiplatelet Therapy, Diabetic Neuropathy and Peripheral Vascular Disease: A Unitary Approach

  2012influential citation
• Platelet and Coagulation / Fibrinolysis Systems in Diabetes Platelets participate in the blood haemostasis in case of blood

  2012influential citation
• Effects of buflomedil on skin blood flow in patients with type 2 diabetes mellitus without overt micro- or macroangiopathy.

  2011cites this paper
• Cilostazol in Diabetic Neuropathy

  2011cites this paper
• Cilostazol: A Pilot Study on Safety and Clinical Efficacy in Neuropathies of Diabetes Mellitus Type 2 (ASCEND)

  2011influential citation
• A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.

  2011cites this paper
• Antiplatelet agents for intermittent claudication.

  2011cites this paper
• Diabetic neuropathy: cellular mechanisms as therapeutic targets

  2011cites this paper
• The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease

  2009influential citation
• Current world literature.

  2009cites this paper
• The prevention of foot ulceration in diabetic patients.

  2009cites this paper